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Abstract
Background: The persistence of latent HIV-1 reservoirs is the principal barrier preventing the
eradication of HIV-1 infection in patients by current antiretroviral therapy. It is thus crucial to
understand the molecular mechanisms involved in the establishment, maintenance and reactivation
of HIV-1 latency. Since chromatin remodeling has been implicated in the transcriptional reactivation
of the HIV-1 promoter, we assessed the role of the histone deacetylase inhibitor sodium butyrate
(NaB) on two HIV-1 latently infected cell lines (U1 and ACH-2) gene expression.
Results: Analysis of microarrays data led us to select two candidate genes: NCoA3 (Nuclear
Receptor Coactivator 3), a nuclear receptor coactivator and IRF8 (Interferon Regulatory Factor 8),
an interferon regulatory factor. NCoA3 gene expression is upregulated following NaB treatment of
latently infected cells whereas IRF8 gene expression is strongly downregulated in the promonocytic
cell line following NaB treatment. Their differential expressions were confirmed at the
transcriptional and translational levels. Moreover, NCoA3 gene expression was also upregulated
after treatment of U1 and ACH-2 cells with phorbol myristyl acetate (PMA) but not trichostatin A
(TSA) and after treatment with NaB of two others HIV-1 latently infected cell lines (OM10.1 and
J1.1). IRF8 gene is only expressed in U1 cells and was also downregulated after treatment with PMA
or TSA. Functional analyses confirmed that NCoA3 synergizes with Tat to enhance HIV-1
promoter transcription and that IRF8 represses the IRF1-mediated activation through the HIV-1
promoter Interferon-stimulated response element (ISRE).
Conclusion: These results led us to postulate that NCoA3 could be involved in the transcriptional
reactivation of the HIV-1 promoter from latency and that IRF8 may contribute to the maintenance
of the latent state in the promonocytic cell line. Implication of these factors in the maintenance or
reactivation of the viral latency may provide potential new targets to control HIV-1 replication in
latent viral reservoirs.
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Background
The use of highly active antiretroviral therapy (HAART) in
HIV-1 infected individuals has led to a significant decrease
of plasma viremia to undetectable levels and has consid-
erably improved the survival and quality of life of infected
individuals (reviewed in [1]). However, the presence of
cellular reservoirs that contain latent viruses capable of
producing infectious particles after cellular activation lead
to a rebound of the viral load after interruption of HAART
(reviewed in [2]). The persistence of these latently infected
viral reservoirs, despite prolonged HAART treatments, rep-
resents a major obstacle to the eradication of HIV-1 in
infected patients [3-5]. Therefore, a greater understanding
of the molecular mechanisms involved in establishment,
maintenance and reactivation of viral latency is essential
to expect the reduction of latent HIV-1 reservoirs in
infected patients.
Latent HIV-1 infection can exist in many reservoirs, such
as macrophages and resting memory CD4+  T cells
(reviewed in [6]). At the cellular level, two major forms of
HIV-1 latency have been described: pre- and post-integra-
tion latency [7]. CD4+ T cells in the post-integration state
of latency represent the most stable reservoir for HIV-1
(half-life of 43 months) [8]. Several mechanisms have
been proposed to account for the low level of transcrip-
tion observed during post-integration latency (reviewed
in [9]): the inaccessibility of the integrated provirus to the
transcriptional machinery, the absence in resting cells of
transcription factors involved in HIV-1 gene expression,
the presence of transcriptional repressors, and the prema-
ture termination of HIV-1 transcription elongation due to
the absence of the viral protein Tat and its associated
cofactors. Moreover, the chromatin structure appears to
be involved in the regulation of HIV-1 gene expression
(reviewed in [10]). Indeed, a repressive nucleosome (nuc-
1), located immediately downstream of the HIV-1 tran-
scription start site under latency conditions, is disrupted
upon transcriptional activation of the HIV-1 promoter in
response to Tat, phorbol esters and histone deacetylase
(HDAC) inhibitors [11]. Transcriptional activation of the
HIV-1 promoter in response to PMA involves the recruit-
ment of SWI/SNF chromatin remodeling complex [12]
and cellular proteins with histone acetyltransferase (HAT)
activity [13]. Therefore, chromatin remodeling plays a sig-
nificant role in the transcriptional reactivation of the HIV-
1 promoter from latency. Identification of host transcrip-
tion factors that may regulate chromatin structure is thus
critical to understand the molecular mechanisms involved
in HIV-1 reactivation.
Gene expression analysis using high-density microarrays
have provided a greater understanding of host-pathogen
interactions (reviewed in [14]). Previous microarray stud-
ies on HIV-1 have described changes in cellular genes tran-
scription in response to HIV-1 protein expression (Nef
[15,16], Tat [17,18], gp120 [19] or Vpr [20]) or following
acute infection of cell lines [21-24] or Peripheral Blood
Mononuclear Cells (PBMC) [25]. DNA microarrays have
also been used to characterize gene expression in latently
infected resting CD4+ T cells in viremic versus aviremic
HIV-1 infected individuals [26]. Recently, global gene
expression changes in cell lines latently infected with HIV-
1 and induced by PMA for completion of viral replication
was described by Krishnan et al. [27].
To complete the results obtained by Krishnan et al., we
used the same strategy to assess the role of the HDAC
inhibitor NaB on HIV-1 latently infected cells gene expres-
sion. We performed microarray experiments on two HIV-
1 latently infected cell lines (U1 and ACH-2) treated or
not with NaB to induce viral reactivation. Analysis of
microarrays data led us to select two candidate genes
encoding transcription factors: NCoA3 (reviewed in [28]),
which expression is upregulated following treatment of
latently infected cells with NaB, and IRF8 (reviewed in
[29]), which expression is downregulated in treated cells.
Differential expression of these genes was confirmed at
the transcriptional and translational levels. Moreover,
NCoA3 gene expression was also upregulated after treat-
ment of U1 and ACH-2 cells with PMA but not TSA and
after treatment with NaB of two others latently infected
cell lines (OM10.1 and J1.1). IRF8 gene is only expressed
in U1 cells and was also downregulated after treatment
with PMA or TSA. Functional analyses confirmed that
NCoA3 synergizes with Tat to enhance HIV-1 promoter
transcription and that IRF8 represses the IRF1-mediated
activation of the HIV-1 ISRE element. Implication of IRF8
in the maintenance and NCoA3 in the reactivation of the
viral latency may thus provide new insights into the con-
trol of HIV-1 replication in latent viral reservoirs.
Results
Microarray analysis
In order to understand the molecular mechanisms regu-
lating HIV-1 latency, we studied the modifications of cel-
lular transcription using microarrays in the promonocytic
U1 and T CD4+ lymphocytic ACH-2 chronically HIV-1
infected cell lines after reactivation of latency. The two cell
lines were treated with 10 mM of the histone deacetylase
inhibitor NaB. Viral reactivation was monitored by cocul-
ture with P4 indicating cells (Figure 1A) and measuring
gag viral mRNA expression (Figure 1B). Increase in both
β-galactosidase activity and gag mRNA expression showed
that the viral reactivation after NaB treatment was effi-
cient. Total RNAs were extracted after 24 h and sent to the
Affymetrix Microarray Facilities for subsequent hybridiza-
tion on U-133A microarrays.Retrovirology 2005, 2:73 http://www.retrovirology.com/content/2/1/73
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The pattern of cellular mRNA from chronically infected
cells treated with NaB was compared to that from non-
treated cells. We used as specific criteria a log2 ratio change
≥ 1 with a change p-value ≤ 0.0001 for increased genes
and a log2 ratio change ≤ -1 with a 1-change p-value ≥
0.9999 for decreased genes. Hybridization experiments
were performed once. We identified 740 genes that were
upregulated by twofold or higher in NaB treated U1 cells
and 896 genes that were downregulated, 482 genes in NaB
treated ACH-2 cells that had a level increased greater than
twofold and 634 genes that had a level decreased greater
than twofold (data not shown). Moreover, 260 genes were
commonly increased and 337 genes were decreased in
both U1 and ACH-2 NaB-treated cells (data not shown).
Pathways involved in regulation of transcription, signal
transduction, immune response, protein transport,
metabolism, apoptosis and RNAs modifications showed
altered expression following treatment with NaB. Some of
the genes involved in these pathways are shown in Addi-
tional Files 1, 2, 3, 4, 5 and 6. Our analysis identified
genes that have previously been associated with HIV-1
replication or latency, such as CDK9 [16], Jun [16,23],
PSMB10 [27], MAPK1 [26] or OAS1 [30]. This supported
the accuracy of our approach, even though, as the hybrid-
ization experiments had been performed once, the statis-
tical relevance of the results could not be estimated.
Among the differentially expressed genes, we chose to
focus on two candidate genes encoding transcription fac-
tors: NCoA3 and IRF8 (Tables 1 and 2). We selected these
two genes based on their biological properties, their
described effects on viral replication [31,32] and their dif-
ferential expression observed by microarray experiments.
Indeed, NCoA3 and IRF8 gene expression are respectively
upregulated and downregulated following treatment with
NaB of latently infected cells (Tables 1 and 2). Therefore,
NCoA3 and IRF8 could be implicated respectively in the
reactivation and maintenance of HIV-1 latency.
NCoA3  gene expression is upregulated following treat-
ment with NaB of both U1 and ACH-2 latently infected
cells (Tables 1 and 2). NCoA3 is a nuclear receptor coacti-
vator of the Steroid Receptor Coactivator (SRC) family
that interacts with nuclear receptors in a ligand-dependent
manner and enhances transcriptional activation via his-
tone acetylation and recruitment of general transcription
factors and additional cofactors (reviewed in [28]).
NCoA3 (Unigene Hs. 382168) gene expression in U1 cells
is significantly upregulated by 4.9 to 22.6 fold
(U1NaBvsU1 signal log2 ratio ranging from 2.3 to 4.5 with
a change p-value < 0.00015) following treatment with
NaB (Table 1). Similarly, NCoA3 gene expression is upreg-
ulated in NaB-treated compared to non-treated ACH-2
cells by 2 to 13.9 fold but with a lower significance
(ACH2NaBvsACH2 signal log2 ratio ranging from 1 to 3.8
with a change p-value < 0.0055) (Table 2).
IRF8 gene expression is downregulated following treat-
ment of U1 cells with NaB (Table 1). IRF8 is a transcrip-
tion factor of the Interferon (IFN) Regulatory Factor (IRF)
family that binds to IFN-stimulated response element and
regulates expression of genes stimulated by IFNs
(reviewed in [29]). IRF8  (Unigene Hs. 137427) is
expressed in the promonocytic cell line U1 (detection sig-
nal of 707.9 with a p-value of 0.000244) (Table 1) but is
not expressed in the T CD4+ lymphocytic cell line ACH-2
(data not shown). Following NaB treatment, IRF8 gene
expression in U1 cells is downregulated by 16 fold
Analysis of viral reactivation after treatment of U1 and ACH- 2 cells with NaB Figure 1
Analysis of viral reactivation after treatment of U1 
and ACH-2 cells with NaB. U1 and ACH-2 cells were 
treated or not (NT) with 10 mM of NaB for 24 h and cocul-
tured with P4 indicating cells. β-galactosidase activity was 
determined after 24 h coculture (A). RNA from U1 and 
ACH-2 cells treated or not with NaB were extracted after 
24 h and gag viral mRNA expression was measured by real-
time RT-PCR (B). Results are representative of three inde-
pendent experiments.
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(U1NaBvsU1 signal log2 ratio of -4 with a 1-change p-
value of 0.99998) (Table 1).
Validation of NCoA3 and IRF8 differential transcriptional 
expression
Real-time RT-PCR quantifications were performed to con-
firm that NCoA3 and IRF8 genes were differentially
expressed in the NaB-treated chronically infected cells
compared to the non-treated cells. We performed quanti-
fication on RNA samples obtained from five independent
NaB treatments of U1 and ACH-2 cells and real-time RT-
PCR experiments were run in duplicate. NCoA3 and IRF8
expressions were normalized to the expression of Cyclo-
philin A. The results show in Figure 2 represent the
NCoA3 expression increase fold (Figure 2A) obtained
from U1 and ACH-2 cells and the IRF8 expression
decrease fold (Figure 2B) obtained from U1 cells treated
with NaB for 24 h and 48 h compared to non-treated cells.
Concerning NCoA3, real-time RT-PCR showed an upregu-
lation consistent with microarray data in 24 h NaB-treated
U1 cells of 8.34 ± 2.42 fold compared to non-treated cells
(Figure 2A). NCoA3 gene expression is also increased with
a 48 h NaB treatment (upregulation of 8.40 ± 2.33 fold)
(Figure 2A). Similarly, an increase of NCoA3 gene expres-
sion can be observed on ACH-2 cells following treatment
with NaB (upregulation of 4.56 ± 1.28 fold in 24 h and
6.80 ± 2.34 fold in 48 h NaB-treated ACH-2 cells) (Figure
2A). Concerning IRF8, real-time RT-PCR showed a 14.96
± 4.85 fold decrease in 24 h NaB-treated U1 cells (Figure
2B) in correlation with the microarray ratio previously
obtained. Downregulation of IRF8 gene expression is also
observed following 48 h NaB-treatment of U1 cells (22.06
± 11.29 fold decrease) (Figure 2B). Taken together, results
from real-time RT-PCR performed on NCoA3 and IRF8
genes corroborate with those obtained using microarray
hybridizations.
We next determined whether NCoA3  and  IRF8  gene
expression were similarly modified in the uninfected
parental cell lines. U937 and CEM cells were subjected to
identical treatment and RT-PCR quantifications were per-
formed (Figure 3). NCoA3 is upregulated both in U937
and CEM cells following treatment with NaB (upregula-
tion of 7.32 ± 1.74 fold in 24 h and 11.45 ± 2.95 fold in
48 h NaB-treated U937 cells, upregulation of 1.93 ± 1.04
fold in 24 h and 5.59 ± 0.06 fold in 48 h NaB-treated CEM
cells) (Figure 3A). IRF8 is only expressed in the promono-
cytic cell line U937 and, as in U1 cells, its expression was
downregulated after NaB treatment (downregulation of
17.95 ± 4.15 fold in 24 h and 22.32 ± 10.82 fold in 48 h
NaB-treated U937 cells) (Figure 3B). Thus, NaB treatment
modify NCoA3 and IRF8 gene expression in uninfected
parental cell lines U937 and CEM at a similar level than in
chronically infected cells.
We then performed additional experiments to determine
whether the gene expression variations observed could
also be mediated by treatments with the phorbol ester
PMA and another HDAC inhibitor, TSA. We thus assessed
the differential regulation of NCoA3 and IRF8 gene expres-
sion in U1 and ACH-2 cells treated with PMA or TSA (Fig-
ure 4). Results indicated that NCoA3  expression is
upregulated by 24 h and 48 h PMA treatment of U1 and
ACH-2 cells (upregulation of 5.70 ± 1.37 fold in 24 h and
9.85 ± 0.90 fold in 48 h PMA-treated U1 cells, upregula-
tion of 3.12 ± 1.05 fold in 24 h and 7.12 ± 1.20 fold in 48
h PMA-treated ACH-2 cells (Figure 4A). However, TSA
treatment had no significant effect on NCoA3 expression
in U1 and ACH-2 cells, although TSA increased viral
expression (data not shown). Concerning IRF8 expression
in U1 cells, PMA and TSA treatments for 24 h induced a
decrease of 3.22 ± 0.45 fold and 5.32 ± 1.09 fold, respec-
tively (Figure 4B). These results show that NCoA3 expres-
Table 1: Differential gene expression obtained for NCoA3 and IRF8 mRNAs in U1 cells treated or not with NaB.
Gene Probe set Name a U1 Signal b U1 Detection p-
value c
U1NaB Signal U1NaB Detection 
p-value
U1NaBvsU1 Signal 
log2 ratio d
U1NaBvsU1 
Change p-value e
NCoA3 207700_s_at 17.7 0.01416 98.9 0.000244 2.5 0.000035
209060_x_at 16.9 0.171387 77.2 0.000244 2.3 0.000023
209061_at 48.4 0.037598 166.4 0.000732 2.3 0.00002
209062_x_at 6.3 0.72583 91.8 0.010742 4.5 0.000147
211352_s_at 7.2 0.303711 68.6 0.00293 3.2 0.000101
IRF8 204057_at 707.9 0.000244 47 0.010742 -4 0.99998
a Affymetrix U133-A reference probe set.
b Signal intensity of hybridization.
c Signal detection p-value < 0.048 for specific hybridization.
d Signal log2 ratio > 1 for increased genes and < -1 for decreased genes.
e Change p-value < 0.0001 for significant increased genes and 1-change p-value > 0.9999 for significant decreased genes.Retrovirology 2005, 2:73 http://www.retrovirology.com/content/2/1/73
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sion is upregulated following phorbol ester but not with
other HDAC inhibitor treatments in U1 and ACH-2 cells.
Moreover, IRF8 gene expression in U1 cells is downregu-
lated with PMA or TSA treatments but at a lower extent
than with NaB.
We also assessed the differential regulation of NCoA3 and
IRF8 gene expression in others chronically HIV-1 infected
cell lines. The chronically infected promonocytic OM10.1
and T CD4+ lymphocytic J1.1 cell lines were treated with
NaB for 24 h and 48 h and real-time RT-PCR were per-
formed to measure NCoA3 and IRF8 gene expression. As
shown in Figure 5, NCoA3 expression is upregulated by
4.94 ± 0.78 fold in OM10.1 and by 2.56 ± 0.64 fold in J1.1
after 24 h NaB treatment. NCoA3 expression increased
with time of NaB treatment in both cell lines (upregula-
tion of 12.89 ± 3.10 fold in OM10.1 and 3.51 ± 0.69 fold
in J1.1 cells) (Figure 5). Like ACH-2 and unlike U1 cells,
the T CD4+  lymphocytic J1.1 and the promonocytic
OM10.1 cell lines did not express IRF8 (data not shown).
Thus, the differential regulation of NCoA3 but not IRF8
gene expression is similar in two other related latently
HIV-1 infected cell line models.
gag mRNA activation is correlated with NCoA3 mRNA 
increase and IRF8 mRNA decrease
We performed reactivation experiments at different times,
sooner than 24 h and until 48 h. Quantitative RT-PCR
experiments were carried out on total RNAs. This was
done using U1 cells to analyze both NCoA3 mRNA
increase (Figure 6A) and IRF8 mRNA decrease (Figure 6B)
relative to HIV gag mRNA along with ACH-2 cells (Figure
6C) to analyze NCoA3 mRNA increase relative to HIV gag
mRNA.
As observed on Figure 6C, the obtained results, both on
ACH-2 and U1 cells, clearly show that gag mRNA activa-
tion occurs after NCoA3 mRNA increase and accumula-
tion. Moreover, in U1 cells, gag mRNA activation occurs
after IRF8 mRNA decrease. Shorter kinetics (0 to 8 h) cor-
related with these results (data not shown).
Validation of NCoA3 and IRF8 differential translational 
expression
To confirm that the changes seen at the RNA level corre-
lated with protein levels, we performed Western blot
experiments on nuclear extract of U1, ACH-2, OM10.1
and J1.1 cells treated or not with NaB for 24 h (Figure 7).
Results indicated that NaB increased the expression level
of NCoA3 protein in U1, ACH-2, OM10.1 and not in J1.1
cells (Figure 7). Moreover, IRF8 protein expression is
strongly downregulated in U1 cells following NaB treat-
ment (Figure 7). These results correlate with the differen-
tial expression of NCoA3 and IRF8 genes observed with
both microarray and real-time RT-PCR experiments.
Transcriptional activation of the HIV-1 promoter by 
NCoA3
We analyzed the functional role of NCoA3 on viral tran-
scription by transfection assays. HEK293 cells were
cotransfected with pLTRX-luc reporter plasmid containing
the luciferase gene under the control of the HIV-1 U3-R
promoter region (nt -640 to +78) with or without Tat and/
or NCoA3 expression vectors. As shown in Figure 8,
NCoA3 increased Tat-stimulated HIV-1 LTR activity by 2.8
± 1.4 fold. The presence of NCoA3 had synergistic effect
on the HIV-1 LTR activity induced by suboptimal expres-
sion of Tat. When HEK293 cells were transfected with
pLTR∆TAR-luc reporter plasmid lacking the Tat-transacti-
vation response element TAR, Tat was not able to activate
the LTR transcription, as expected, and NCoA3 had no
effect on the LTR activity (Figure 8). Thus, functional anal-
yses confirm that NCoA3 synergizes with Tat to enhance
HIV-1 promoter transcription, as expected [31], and that
this effect is dependent on the presence of the TAR region.
Table 2: Differential gene expression obtained for NCoA3 mRNA in ACH-2 cells treated or not with NaB.
Gene Probe set Name a ACH-2 Signal b ACH-2 Detection 
p-value c
ACH2NaB 
Signal
ACH2NaB 
Detection p-value
ACH2NaBvsACH
2 Signal log2 ratio d
ACH2NaBvsACH2 
Change p-value e
NCoA3 207700_s_at 43.3 0.001953 99.6 0.001221 1.2 0.000241
209060_x_at 34.5 0.01416 72.9 0.001953 1 0.000273
209061_at 65.8 0.000732 82.6 0.000732 1.6 0.005409
209062_x_at 20 0.466064 76.7 0.095215 2 0.000114
211352_s_at 2.7 0.5 37 0.030273 3.8 0.004481
a Affymetrix U133-A reference probe set.
b Signal intensity of hybridization.
c Signal detection p-value < 0.048 for specific hybridization.
d Signal log2 ratio > 1 for increased genes and < -1 for decreased genes.
e Change p-value < 0.0001 for significant increased genes and 1-change p-value > 0.9999 for significant decreased genes.Retrovirology 2005, 2:73 http://www.retrovirology.com/content/2/1/73
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Transcriptional repression of the HIV-1 ISRE element by 
IRF8
We analyzed the functional role of IRF8 on viral transcrip-
tion by transfection assays. HEK293 cells were cotrans-
fected with pISRE-TK-luc reporter plasmid corresponding
to the HIV-1 IFN-stimulated response element, located
downstream transcription start site (nt +194 to +223)
[33], with or without IRF1 and/or IRF8 expression vectors.
As shown in Figure 9, the basal activity of the ISRE-TK was
increased by 7.4 ± 1.0 fold in the presence of IRF1 as
expected [32], whereas a decrease was detected in the pres-
ence of IRF8 (21.9 ± 10.6 to 41.4 ± 9.5 %). The expression
of IRF8 inhibited by 43.5 ± 10.6 to 74.7 ± 2.5 % the IRF1-
mediated activation of the ISRE-TK in a dose dependent
fashion (Figure 9). The expression of the dominant nega-
tive IRF8 DNA-binding domain (IRF8-DBD) inhibited by
76.4 ± 6.5 % the IRF1-mediated activation of the ISRE-TK,
as expected [34] (Figure 9). The inhibitory effects of IRF8
and IRF8-DBD expression and activation effect of IRF1
expression was abolished when the ISRE sequence was
mutated (pISREmut-TK-luc, Figure 9). These results show
that IRF8 represses the ISRE-TK promoter transcription
Real-time RT-PCR analysis of NCoA3 and IRF8 mRNAs  expression in NaB-treated U937 and CEM cells Figure 3
Real-time RT-PCR analysis of NCoA3 and IRF8 
mRNAs expression in NaB-treated U937 and CEM 
cells. Total RNAs were isolated from U937 or CEM cells 
treated or not with NaB for 24 h and 48 h and real-time PCR 
were performed on cDNAs using gene specific primers for 
NCoA3, IRF8 or Cyclophilin A. NCoA3 and IRF8 expressions 
were normalized to the expression of Cyclophilin A. The 
NCoA3 increase fold (A) in U937 (solid bars) or CEM (white 
bars) cells and the IRF8 decrease fold (B) in U937 cells 
treated with NaB for 24 h and 48 h compared to non-treated 
(NT) cells were determined. Results represent the means of 
five independent experiments performed in duplicate.
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Real-time RT-PCR analysis of NCoA3 and IRF8 mRNAs  expression in NaB-treated U1 and ACH-2 cells Figure 2
Real-time RT-PCR analysis of NCoA3 and IRF8 
mRNAs expression in NaB-treated U1 and ACH-2 
cells. Total RNAs were isolated from U1 or ACH-2 cells 
treated or not with NaB for 24 h and 48 h and real-time PCR 
were performed on cDNAs using gene specific primers for 
NCoA3, IRF8 or Cyclophilin A. NCoA3 and IRF8 expressions 
were normalized to the expression of Cyclophilin A. The 
NCoA3 increase fold (A) in U1 (solid bars) or ACH-2 (white 
bars) cells and the IRF8 decrease fold (B) in U1 cells treated 
with NaB for 24 h and 48 h compared to non-treated (NT) 
cells were determined. Results represent the means of five 
independent experiments performed in duplicate.
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through the ISRE element from the HIV-1 promoter, as
expected [32].
Discussion
The existence of long-lasting HIV-1 reservoirs is the prin-
cipal barrier preventing the eradication of HIV-1 infection
in patients by current antiretroviral therapy. It is thus cru-
cial to understand the molecular mechanisms involved in
establishment, maintenance and reactivation of HIV-1
latency. In this study, the role of the HDAC inhibitor NaB
on HIV-1 latently infected cells gene expression was
explored using microarrays. Since chromatin remodeling
is involved in the regulation of HIV-1 gene expression
(reviewed in [10]), differential expression of cellular genes
in latently infected cells following treatment with NaB
might be related to the maintenance and reactivation of
latency.
Recently, Krishnan et al. [27] described the global gene
expression changes in HIV-1 latently infected cell lines
treated or not with PMA to induce viral reactivation com-
pared to the uninfected parental cell lines treated under
the same conditions. Here, we compared gene expression
profiles of two HIV-1 latently infected cell lines (U1 and
ACH-2) treated with NaB to that of non-treated corre-
sponding cell lines. We thus avoided identification of
genes which differential expression could result from the
establishment and cloning of the chronically infected cell
lines. Based on our specific criteria, we identified few hun-
dreds of genes affected by NaB treatment implicated in
biological pathways previously shown to be modulated
by HIV-1 replication. For example, reactivation of latency
induced an upregulation of CDK9, the catalytic compo-
nent of transcription elongation factor b (P-TEFb), which
acts in concert with Tat to direct the processivity of HIV-1
transcription. It was shown that CDK9 mRNA and protein
levels are induced following T cell activation and Nef
Real-time RT-PCR analysis of NCoA3 mRNAs expression in  OM10.1 and J1.1 cells Figure 5
Real-time RT-PCR analysis of NCoA3 mRNAs 
expression in OM10.1 and J1.1 cells. Total RNAs were 
isolated from OM10.1 or J1.1 cells treated or not with NaB 
for 24 h and 48 h and real-time PCR were performed on 
cDNAs using gene specific primers for NCoA3 or Cyclophilin 
A. NCoA3 expression was normalized to the expression of 
Cyclophilin A. The NCoA3 increase fold in OM10.1 (solid bars) 
or J1.1 cells (white bars) treated with NaB for 24 h and 48 h 
compared to non-treated (NT) cells were determined. 
Results represent the means of two independent experi-
ments performed in duplicate.
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Real-time RT-PCR analysis of NCoA3 and IRF8 mRNAs  expression in PMA- or TSA-treated U1 and ACH-2 cells Figure 4
Real-time RT-PCR analysis of NCoA3 and IRF8 
mRNAs expression in PMA- or TSA-treated U1 and 
ACH-2 cells. Total RNAs were isolated from U1 or ACH-2 
cells treated or not with PMA for 24 h and 48 h or TSA for 
24 h and real-time PCR were performed on cDNAs using 
gene specific primers for NCoA3, IRF8 or Cyclophilin A. NCoA3 
and IRF8 expressions were normalized to the expression of 
Cyclophilin A. The NCoA3 increase fold (A) in U1 (solid bars) 
or ACH-2 (white bars) cells treated with PMA for 24 h and 
48 h and the IRF8 decrease fold (B) in U1 cells treated with 
PMA or TSA for 24 h compared to non-treated (NT) cells 
were determined. Results represent the means of three inde-
pendent experiments performed in duplicate.
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expression, and that this correlates with kinase activity,
thus enhancing HIV-1 transcription [16,35].
After NaB treatment of latently infected cell lines, we
observed an upregulation of genes involved in vesicular
transport of protein like syntaxin and nexin. It was found
by Chun et al. that numerous genes involved in protein/
vesicle transport are upregulated in resting T CD4+ cells of
viremic patients, strongly suggesting that enhanced activi-
ties in secretory pathways may help in the assembly and
release of viral particles [26]. Recently, it was shown that
multiple genes involved in cholesterol synthesis are
induced by Nef [36]. NaB treatment also induced some of
these genes (INSIG1, HMGCS1, IDI1, LSS or SREBF1) and
could thus enhanced virion infectivity and viral replica-
tion.
Krishnan et al. have described an increase in expression of
several proteasome subunits in ACH-2 cells prior induc-
tion of lytic replication by PMA and proposed that the
higher expression of proteasomes may lead to increased
degradation of HIV-1 mRNA [27]. After induction of lytic
replication by NaB, proteasome subunits PSMB10 and
PSMB8 were downregulated in ACH-2 and U1 cells, sug-
gesting a role in the maintenance of the latent state.
Indeed, reactivation of latency was achieved with proteas-
ome inhibitors [27]. Among the downregulated genes
after NaB treatment, we identified genes involved in RNA
modifications. Krishnan et al. have shown alterations in
the expression of DEAD-box and other RNA binding pro-
teins during HIV-1 replication [37]. Especially, DDX18
and DDX39 are upregulated in latently infected cells [37].
After NaB treatment of latently infected cells, we observed
a decrease in the expression of these two proteins, thus
providing more support for their role in maintaining HIV-
1 latency.
The only purpose of our microarray analysis was to iden-
tify candidate genes potentially involved in the control of
the HIV latency. For this reason, we decided to focus on
two candidate genes previously described to influence
viral expression and that may be involved in reactivation
and maintenance of latency: NCoA3  and  IRF8, respec-
tively. Hybridization experiments were performed once.
Consequently, we did not further analyze the statistical
relevance of the results and performed complementary
approaches to confirm the mRNA variations of the
selected candidate genes.
NCoA3 is a nuclear receptor coactivator that enhances lig-
and-induced transcriptional activation of nuclear recep-
tors (reviewed in [28]). We show that NCoA3 (Unigene
Hs. 382168) gene expression is upregulated following
treatment with NaB of U1 and ACH-2 latently infected
cells. This differential transcriptional expression was con-
firmed by real-time RT-PCR and is also mediated by PMA
but not TSA. Upregulation of NCoA3 is thus achieved fol-
lowing phorbol ester but not other HDAC inhibitor treat-
ment. However, NaB and TSA act on different pathways
and at different concentrations and target different genes
[38]. Transcriptional increase of NCoA3 was observed in
parental uninfected corresponding cell lines U937 and
CEM and in two others latently HIV-1 infected cell lines,
OM10.1 and J1.1. NCoA3 protein level is also upregulated
following treatment with NaB in the U1, ACH-2 and
Analysis of HIV gag, NCoA3, and IRF8 mRNA expression after  NaB stimulation on U1 and ACH-2 cells Figure 6
Analysis of HIV gag, NCoA3, and IRF8 mRNA expres-
sion after NaB stimulation on U1 and ACH-2 cells. U1 
(A and B) and ACH-2 (C) cells were stimulated with 10 mM 
NaB and 5.106 cells were taken at t = 0, 4, 8, 16, 24, 48 h for 
RNA extraction to perform qRT-PCR. NCoA3 (A and C), 
IRF8 (B) and gag (A, B and C) mRNA contents were meas-
ured. Cylophilin A was used as internal standard. Results rep-
resent a representative experiment performed in duplicate.
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OM10.1 cell lines. Moreover, NCoA3 increases the Tat-
induced HIV-1 LTR promoter transcriptional activity
through the TAR region, in accordance with other data
[31]. The differential expression of NCoA3 observed led
us to postulate that NCoA3 could be involved in the tran-
scriptional reactivation of the HIV-1 promoter from
latency, at low concentrations of Tat.
This hypothesis is supported by several findings. Previous
microarray studies on latently infected resting CD4+ T cells
in infected individuals have shown an upregulation of
NCoA3 gene expression in viremic versus aviremic
patients [26]. Moreover, Kino et al. showed that NCoA fac-
tors improve Tat transactivation of HIV-1 LTR promoter
activity and interact with Tat [31]. Tat transactivation
activity is mediated by its interaction with components of
the basal transcription machinery (including TBP,
TAFII250, RNA polymerase II), with kinase complexes
able to phosphorylate the C-terminal domain of RNA
polymerase II (in particular with the P-TEFb complex
composed of cyclin T1/CDK9) and with cellular proteins
possessing HAT activity (p300/CBP, P/CAF and GCN5)
(reviewed in [39]). Kino et al. showed that one member of
the family, NCoA2, functions as a Tat coactivator on the
HIV-1 LTR by bridging promoter-bound proteins with the
Tat-P-TEFb complex through its interaction with Tat and
Cyclin T1 [31]. Stimulation of Tat transactivation activity
by NCoA3 could involve similar mechanisms.
Furthemore, it has been recently demonstrated that
recruitment of HATs to the LTR is an early event in HIV-1
transcriptional activation [13] and that a consequence of
histone acetylation is the recruitment of the ATP-depend-
ent chromatin remodeling complex hSWI/SNF to the LTR
[12]. NCoA3 could mediate chromatin remodeling by
recruitment of additional cofactors with HAT activity
(such as p300/CBP and P/CAF) and by an intrinsic HAT
activity [40] and may thus contribute to the transcrip-
tional reactivation of the HIV-1 promoter from latency.
IRF8 is a transcription factor that binds to ISRE and regu-
lates expression of genes stimulated by IFNs (reviewed in
[29]). IRF8 is able to both activate and repress gene tran-
scription depending on the target gene. We show that
IRF8 (Unigene Hs. 137427) gene is only expressed in the
promonocytic cell line U1 and its expression is strongly
downregulated following NaB treatment of these cells.
This differential transcriptional expression was confirmed
by real-time RT-PCR and is also observed, albeit at lower
extent, after PMA and TSA treatments of U1 cells. IRF8
protein level is similarly downregulated following treat-
ment with NaB. Moreover, IRF8 represses the IRF1-medi-
ated activation of the HIV-1 ISRE element of the LTR, in
accordance with other data [32]. The decreased expression
of IRF8 following reactivation of latency using different
molecules suggest that IRF8 may contribute in the main-
tenance of the latent state in the promonocytic cell line.
It has been shown that binding of specific transcription
factors downstream of the HIV-1 transcription start site is
crucial to control HIV-1 transcription [33,41]. Among
these sites is an ISRE element that recruits IRF1 and IRF2
in vivo [33]. Previous studies have investigated the role of
IRFs on the modulation of HIV-1 replication (reviewed in
[42,43]) and showed that IRF1 activates HIV-1 LTR tran-
scription, interacts with Tat [32] and increases HIV-1 rep-
lication [44]. However, IRF8 represses IRF1-Tat-mediated
transactivation of the LTR by interfering with IRF1-Tat
association [32]. Moreover, it has been shown that IRF8
inhibits HIV-1 replication in T CD4+ lymphocytic and
promonocytic cell lines [32,34]. These data support the
hypothesis that repression of HIV-1 transcription by IRF8
could be implicated in the maintenance of proviral quies-
cence in latently infected cells.
Moreover, the result obtained after measurement of gag,
NCoA3 and IRF8 mRNA after different times of NaB stim-
ulation clearly showed a correlation between gag mRNA
increase and NCoA3  mRNA increase or IRF8  mRNA
decrease, respectively. These correlations support the
hypothesis that IRF8 and NCoA3 factors may be involved
in the control of the HIV latency.
Western blot analysis of NCoA3 and IRF8 proteins expres- sion Figure 7
Western blot analysis of NCoA3 and IRF8 proteins 
expression. Nuclear extract (100 µg) from U1, ACH-2, J1.1 
and OM10.1 treated (+) or not (-) with NaB for 24 h were 
resolved by SDS-PAGE and immunoblotted with anti-
NCoA3 or anti-IRF8 antibody, as indicated. The amount of 
protein was normalized using anti-actin antibody. Figures 
below NCoA3 immunoblot indicated the results of the quan-
tification using Image Tool (Syngene) software of the ratio 
NCoA3/actin upon NaB-treatment (+) versus NCoA3/actin 
non-treated (-). Results are representative of three inde-
pendent experiments.
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Chronically HIV-1 infected cell lines used in this study
provide useful models for studying HIV-1 latency but are
not in a quiescent state as cellular reservoirs in vivo. More-
over, it has been shown that mutations in the tat gene and
in the TAR sequence are responsible for the latency
observed in U1 and ACH-2 cells, respectively [45,46]. We
thus confirmed the differential expression of NCoA3 but
not IRF8 genes in two others chronically HIV-1 infected
cell lines, OM10.1 and J1.1. We will now investigate the
involvement of NCoA3 and IRF8 to regulate viral expres-
sion in primary cells such as resting T CD4+ lymphocytes
or macrophages.
Conclusion
Additional experiments are currently underway to validate
the biological relevance of the differential expression of
IRF8 and NCoA3 genes in latency maintenance and reac-
tivation. Since the persistence of integrated HIV-1
genomes despite potent suppression of viral replication is
a major obstacle for current antiretroviral therapy, selec-
tive disruption of the HIV-1 proviral latency may provide
good strategies to decrease latent HIV-1 reservoirs. Thus,
identification of cellular genes that are differentially
expressed during HIV-1 reactivation of latency is crucial to
understand the molecular mechanisms involved in the
control of HIV-1 latency.
Methods
Cell cultures and treatments
The chronically HIV-1 infected T CD4+ lymphocytic cell
lines ACH-2 [47] and J1.1 [48] derived from CEM and Jur-
kat cells respectively, and the chronically HIV-1 infected
promonocytic cell lines U1 [49] and OM10.1 [50] derived
from U937 and HL-60 cells respectively, were obtained
through the National Institutes of Health (NIH) AIDS
Research and Reference Reagent Program. Suspension cell
lines were grown in RPMI 1640 (Invitrogen) with 10%
fetal bovine serum (Invitrogen), 50 U/mL penicillin, 50
µg/mL streptomycin (Invitrogen) and 2 mM glutamine
(Invitrogen). Cells were treated with 10 mM of sodium
butyrate (NaB; Sigma), or with 10 ng/mL of PMA (Sigma),
or with 300 nM of TSA (Sigma). Cells were harvested gen-
erally 24 h and 48 h after treatment and cell viability was
estimated before subsequent RNA extraction or nuclear
extract preparation. P4 indicator cells are HeLa CD4+ cells
carrying the lacZ gene under the control of the HIV-1 LTR.
P4 and HEK293 cells were grown in DMEM (Invitrogen)
containing 5% fetal bovine serum (Invitrogen), 50 U/mL
penicillin, 50 µg/mL streptomycin (Invitrogen) and 2 mM
glutamine (Invitrogen).
Plasmids
The pLTRX-luc construct contains the luciferase (luc) gene
downstream of the HIV-1 BRU U3-R promoter region (nt
-640 to +78) [51]. The pLTR∆TAR-luc construct corre-
sponds to the pLTRX-luc plasmid in which the TAR region
(nt +38 to +78) was deleted [51]. The pCMV-Tat expres-
sion vector was kindly provided by S. Emiliani (Institut
Cochin, Paris, France). The pIRF8 expression vector (pcD-
NAmycHis-ICSBP) and dominant negative construct
pIRF8-DBD, which contains the DNA binding domain of
IRF8, were a kind gift of B.Z. Levi (Technion-Israel Insti-
tute of Technology, Haifa, Israel). The pNCoA3 expression
vector (pcDNA3.1-AIB1) was a kind gift of P.S. Meltzer
(NIH, Bethesda, USA) [52]. The pIRF1 construct was gen-
erated by cloning the fragment excised from pHuIRF-3-1
(a kind gift of T. Taniguchi, University of Tokyo, Tokyo,
Japan) by HindIII/NotI digestion in the pcDNA3.1 plas-
mid (Invitrogen). The pISRE-TK-luc and pISREmut-TK-luc
constructs were generated by cloning a wild-type
(AGGGACTTGAAAGCGAAAGGGAAACCAGAG) or
mutated (AGGGACTTGCCCGCGCCCGGGAAACCA-
GAG) synthetic oligonucleotide corresponding to the
HIV-1 BRU ISRE sequence (nt +194 to +223) [33,53] in
the pTK-luc plasmid in which the luciferase gene is under
the control of the truncated HSV-1 thymidine kinase pro-
moter minimum region [51]. The pCMV-LacZ was kindly
provided by M. Alizon (Institut Cochin, Paris, France).
Total RNA extraction
Total RNAs were extracted using the RNeasy Mini Kit
(Qiagen). The procedure included an "on-column"
NCoA3 increases the Tat-stimulated HIV-1 LTR activity Figure 8
NCoA3 increases the Tat-stimulated HIV-1 LTR 
activity. HEK293 cells were cotransfected with pLTRX-luc 
(10 ng, grey bars) or pLTR∆TAR-luc (10 ng, white bars) with 
(+) or without (-) suboptimal amounts of pCMV-Tat (5 ng) 
and/or pNCoA3 (1 µg) expression vectors. NLI (normalized 
luciferase index) were measured after 24 h and the activation 
folds compared to the basal activity of the corresponding 
pLTR-luc were determined. Results represent the means of 
five independent experiments.
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DNase I digestion step according to the manufacturer's
instructions. RNA quality was assessed using the Agilent
Bioanalyzer 2100 and spectrophotometric analysis prior
to cDNA synthesis.
Microarray experiments
Microarray experiments were performed using the U133-
A microarrays (Affymetrix) containing 22283 oligonucle-
otides spots. Total RNAs obtained from chronically
infected U1 and ACH-2 stimulated or not with NaB for 24
h were sent to Dr. C. Thibault (Affymetrix Microarray
Facilities, IGBMC, Strasbourg, France) for amplification,
labeling and hybridization. Hybridization experiments
were performed once. Results were then analyzed with the
Mas5.0 Software (Affymetrix) and interpreted using the
Data Mining Tool (Affymetrix) and Microsoft Excel soft-
wares. For individual analyses, the p-value cut off was
0.048 as suggested by Affymetrix. For comparative analy-
ses, a log2 ratio change ≥ 1 for increased genes and ≤ -1 for
decreased genes were defined. Gene expression changes
were considered to be significant when the change p-value
was ≤ 0.0001 for increased genes and 1-change p-value ≥
0.9999 for decreased genes.
Real-time RT-PCR
Quantifications of cellular RNAs were performed using a
Light Cycler instrument (Roche Diagnostics). Briefly,
cDNAs were synthesized from 1 µg of total RNA with
MoMLV reverse transcriptase (Superscript II, Invitrogen)
and 1/10th aliquots of the corresponding samples were
used for real-time PCR in a 20 µL reaction mixture con-
taining 1X LightCycler FastStart DNA Master SYBR Green
I (Roche Diagnostics), 4 mM MgCl2, and 500 nM of each
primer. The reactions were carried out in duplicate and the
results were normalized to the expression of Cyclophilin
A. Primers for quantitative PCR were designed using Oligo
6 software. All primer pairs produced single amplification
product as determined by melting curve analyses. The
sequences of the primers used were (5' to 3'): NCoA3 for-
ward CTTTGGGCATTCCTGAACTTGTC, NCoA3 reverse
GCCTCATCACCGCAGCAC, IRF8 forward GGAGTGCG-
GTCGCTCTGAAA, IRF8 reverse GTCGTAGGTGGTGTAC-
CCCGTCA, Cyclophilin A forward
AGTGGTTGGATGGCAAGC, Cyclophilin A reverse GAT-
TCTAGGATACTGCGAGCAAA. PCR reactions were car-
ried out with a denaturation step of 10 min at 95°C
followed by forty-five cycles of 10 s at 95°C, 5 s at anneal-
ing temperature (55°C for NCoA3 and Cyclophilin A,
59°C for IRF8) and 20 s amplification at 72°C. Quantifi-
cations of cDNAs were determined in reference to a stand-
ard curve prepared by amplification of serial dilutions of
PCR product containing matching sequences. Analyses
were performed using the second-derivative-maximum
method provided by the Light Cycler quantification soft-
ware, version 3.5 (Roche Diagnostics).
Quantification of gag viral mRNA was performed by real-
time RT-PCR as described in [54].
Nuclear extracts preparation
For nuclear extract preparation, 10.106 cells were har-
vested, washed and nuclei were isolated by addition of
150 µL of buffer I (50 mM Tris pH 7.9, 10 mM KCl, 10%
glycerol, 1 mM EDTA, 0.2% NP40) followed by a centrif-
ugation at 3000 g for 3 min. Nuclear extracts were pre-
pared by addition of 15 µL of buffer II (20 mM Hepes pH
7.9, 400 mM NaCl, 10 mM KCl, 20% glycerol, 1 mM
EDTA) for 20 min at 4°C followed by a centrifugation at
15000 g for 10 min. Protein concentrations were deter-
mined by the Bio-Rad protein assay.
Western blot analysis
Nuclear extracts (100 µg) were loaded on 8% SDS-poly-
acrylamide gel and the proteins were transferred to nitro-
cellulose membrane (Hybond-C, Amersham) that was
subsequently blocked for 1 h with 5% non-fat dry milk in
PBS-T (PBS, 0.05% Tween20) and incubated with anti-
bodies directed against NCoA3 (goat polyclonal anti-
ACTR C-20, Santa Cruz Biotechnology, Inc.), IRF8 (goat
polyclonal anti-ICSBP C-19, Santa Cruz Biotechnology,
Inc.) or actin (mouse monoclonal anti-actin, Calbio-
chem) for 2 h. The membranes were then washed and
incubated with secondary antibodies conjugated to horse-
radish peroxidase (HRP conjugated rabbit anti-goat
(DakoCytomation) or goat anti-mouse (Calbiochem)
IRF8 represses the IRF1-mediated activation of the HIV-1  ISRE element Figure 9
IRF8 represses the IRF1-mediated activation of the 
HIV-1 ISRE element. HEK293 cells were cotransfected 
with pISRE-TK-luc (250 ng, solid bars) or pISREmut-TK-luc 
(250 ng, white bars) with (+) or without (-) pIRF1 (250 ng), 
pIRF8 (1–2.5 µg), or pIRF8-DBD (1 µg) expression vectors. 
NLI (normalized luciferase index) were measured after 24 h 
and the activation folds compared to the basal activity of the 
pISRE-TK-luc or pISREmut-TK-luc were determined. Results 
represent the means of five independent experiments.
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immunoglobulins). Hybridizations were revealed using
an ECL enhanced chemiluminescence kit (ECL, Amer-
sham). The quantification was done using the Image
Tools (Syngene) software.
Transient transfection and enzymatic assays
HEK293 cells were transfected using calcium phosphate
co-precipitation method. Cells were lysed 24 h after trans-
fection with a buffer containing 60 mM Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 10 mM MgSO4, 2.5 mM EDTA, 50
mM β-mercaptoethanol and 0.125% Nonidet P-40. Luci-
ferase activities were measured as previously described
[55]. Cotransfection with pCMV-LacZ plasmid was per-
formed to normalize transfection efficiency and β-galac-
tosidase activities were determined using Chlorophenol
red  β-D-galactopyranoside (CPRG, Roche Diagnostics)
assay as previously described [55]. The normalized luci-
ferase index (NLI) was defined as the ratio of luciferase to
β-galactosidase activities.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SM performed the microarray analyses, real-time RT-PCR
and drafted the manuscript. DD and LC carried out real-
time RT-PCR, Western blot and transfection experiments.
AG participated in transfection experiments. UH con-
ceived the study, participated in its design and coordina-
tion and helped to draft and finalize the manuscript. All
authors read and approved the final manuscript.
Additional material
Acknowledgements
We thank Drs. S. Emiliani, B.Z. Levi, P.S. Meltzer, T. Taniguchi, M. Alizon 
for providing plasmids, and the National Institutes of Health AIDS Research 
and Reference Reagent Program for the kind gift of reagents. We are grate-
ful to Dr. C. Thibault for her precious help in microarray hybridization data 
mining. L.C. holds a fellowship from the Ministère de l'Education Nationale, 
de l'Enseignement Supérieur et de la Recherche. S.M. is supported by a 
grant from Sidaction. Sidaction (AO15) supported this work. We thank S. 
Nisole for helpful discussion.
References
1. Pomerantz RJ, Horn DL: Twenty years of therapy for HIV-1 infection.
Nat Med 2003, 9:867-873.
2. Pierson T, McArthur J, Siliciano RF: Reservoirs for HIV-1: mecha-
nisms for viral persistence in the presence of antiviral
immune responses and antiretroviral therapy.  Annu Rev Immu-
nol 2000, 18:665-708.
3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA,
Richman DD: Recovery of replication-competent HIV despite
prolonged suppression of plasma viremia.  Science 1997,
278:1291-1295.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE,
Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J,
Markowitz M, Ho DD, Richman DD, Siliciano RF: Identification of
a reservoir for HIV-1 in patients on highly active antiretrovi-
ral therapy.  Science 1997, 278:1295-1300.
5. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd
AL, Nowak MA, Fauci AS: Presence of an inducible HIV-1 latent
reservoir during highly active antiretroviral therapy.  Proc Natl
Acad Sci U S A 1997, 94:13193-13197.
6. Blankson JN, Persaud D, Siliciano RF: The challenge of viral reser-
voirs in HIV-1 infection.  Annu Rev Med 2002, 53:557-593.
7. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF: The multifactorial
nature of HIV-1 latency.  Trends Mol Med 2004, 10:525-531.
8. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T,
Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE,
Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF: Latent
infection of CD4(+) T cells provides a mechanism for lifelong
persistence of HIV-1, even in patients on effective combina-
tion therapy.  Nat Med 1999, 5:512-517.
9. Williams SA, Greene WC: Host factors regulating post-integra-
tion latency of HIV.  Trends Microbiol 2005, 13:137-139.
10. He G, Ylisastigui L, Margolis DM: The regulation of HIV-1 gene
expression: the emerging role of chromatin.  DNA Cell Biol
2002, 21:697-705.
Additional File 1
Genes upregulated in U1 and ACH-2 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-2-73-S1.doc]
Additional File 2
Genes specifically upregulated in U1 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-2-73-S2.doc]
Additional File 3
Genes specifically upregulated in ACH-2 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-2-73-S3.doc]
Additional File 4
Genes downregulated in U1 and ACH-2 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-2-73-S4.doc]
Additional File 5
Genes specifically downregulated in U1 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-2-73-S5.doc]
Additional File 6
Genes specifically downregulated in ACH-2 cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-2-73-S6.doc]Retrovirology 2005, 2:73 http://www.retrovirology.com/content/2/1/73
Page 13 of 14
(page number not for citation purposes)
11. Verdin E, Paras PJ, Van Lint C: Chromatin disruption in the pro-
moter of human immunodeficiency virus type 1 during tran-
scriptional activation.  Embo J 1993, 12:3249-3259.
12. Henderson A, Holloway A, Reeves R, Tremethick DJ: Recruitment
of SWI/SNF to the human immunodeficiency virus type 1
promoter.  Mol Cell Biol 2004, 24:389-397.
13. Lusic M, Marcello A, Cereseto A, Giacca M: Regulation of HIV-1
gene expression by histone acetylation and factor recruit-
ment at the LTR promoter.  Embo J 2003, 22:6550-6561.
14. Kato-Maeda M, Gao Q, Small PM: Microarray analysis of patho-
gens and their interaction with hosts.  Cell Microbiol 2001,
3:713-719.
15. Shaheduzzaman S, Krishnan V, Petrovic A, Bittner M, Meltzer P, Trent
J, Venkatesan S, Zeichner S: Effects of HIV-1 Nef on cellular gene
expression profiles.  J Biomed Sci 2002, 9:82-96.
16. Simmons A, Aluvihare V, McMichael A: Nef triggers a transcrip-
tional program in T cells imitating single-signal T cell activa-
tion and inducing HIV virulence mediators.  Immunity 2001,
14:763-777.
17. De la Fuente C, Santiago F, Deng L, Eadie C, Zilberman I, Kehn K,
Maddukuri A, Baylor S, Wu K, Lee CG, Pumfery A, Kashanchi F:
Gene expression profile of HIV-1 Tat expressing cells: a close
interplay between proliferative and differentiation signals.
BMC Biochem 2002, 3:14.
18. Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA,
Aldovini A: HIV-1 Tat reprograms immature dendritic cells to
express chemoattractants for activated T cells and macro-
phages.  Nat Med 2003, 9:191-197.
19. Cicala C, Arthos J, Selig SM, Dennis GJ, Hosack DA, Van Ryk D, Span-
gler ML, Steenbeke TD, Khazanie P, Gupta N, Yang J, Daucher M,
Lempicki RA, Fauci AS: HIV envelope induces a cascade of cell
signals in non-proliferating target cells that favor virus repli-
cation.  Proc Natl Acad Sci U S A 2002, 99:9380-9385.
20. Janket ML, Manickam P, Majumder B, Thotala D, Wagner M, Schafer
EA, Collman RG, Srinivasan A, Ayyavoo V: Differential regulation
of host cellular genes by HIV-1 viral protein R (Vpr): cDNA
microarray analysis using isogenic virus.  Biochem Biophys Res
Commun 2004, 314:1126-1132.
21. Corbeil J, Sheeter D, Genini D, Rought S, Leoni L, Du P, Ferguson M,
Masys DR, Welsh JB, Fink JL, Sasik R, Huang D, Drenkow J, Richman
DD, Gingeras T: Temporal gene regulation during HIV-1 infec-
tion of human CD4+ T cells.  Genome Res 2001, 11:1198-1204.
22. Geiss GK, Bumgarner RE, An MC, Agy MB, van 't Wout AB, Ham-
mersmark E, Carter VS, Upchurch D, Mullins JI, Katze MG: Large-
scale monitoring of host cell gene expression during HIV-1
infection using cDNA microarrays.  Virology 2000, 266:8-16.
23. Van 't Wout AB, Lehrman GK, Mikheeva SA, O'Keeffe GC, Katze MG,
Bumgarner RE, Geiss GK, Mullins JI: Cellular gene expression
upon human immunodeficiency virus type 1 infection of
CD4(+)-T-cell lines.  J Virol 2003, 77:1392-1402.
24. Wen W, Chen S, Cao Y, Zhu Y, Yamamoto Y: HIV-1 infection ini-
tiates changes in the expression of a wide array of genes in
U937 promonocytes and HUT78 T cells.  Virus Res 2005.
25. Vahey MT, Nau ME, Jagodzinski LL, Yalley-Ogunro J, Taubman M,
Michael NL, Lewis MG: Impact of viral infection on the gene
expression profiles of proliferating normal human peripheral
blood mononuclear cells infected with HIV type 1 RF.  AIDS
Res Hum Retroviruses 2002, 18:179-192.
26. Chun TW, Justement JS, Lempicki RA, Yang J, Dennis GJ, Hallahan
CW, Sanford C, Pandya P, Liu S, McLaughlin M, Ehler LA, Moir S, Fauci
AS: Gene expression and viral prodution in latently infected,
resting CD4+ T cells in viremic versus aviremic HIV-infected
individuals.  Proc Natl Acad Sci U S A 2003, 100:1908-1913.
27. Krishnan V, Zeichner SL: Host cell gene expression during
human immunodeficiency virus type 1 latency and reactiva-
tion and effects of targeting genes that are differentially
expressed in viral latency.  J Virol 2004, 78:9458-9473.
28. Xu J, Li Q: Review of the in vivo Functions of the p160 Steroid
Receptor Coactivator Family.  Mol Endocrinol 2003, 12:12.
29. Levi BZ, Hashmueli S, Gleit-Kielmanowicz M, Azriel A, Meraro D:
ICSBP/IRF-8 transactivation: a tale of protein-protein inter-
action.  J Interferon Cytokine Res 2002, 22:153-160.
30. Bosinger SE, Hosiawa KA, Cameron MJ, Persad D, Ran L, Xu L, Bou-
lassel MR, Parenteau M, Fournier J, Rud EW, Kelvin DJ: Gene
expression profiling of host response in models of acute HIV
infection.  J Immunol 2004, 173:6858-6863.
31. Kino T, Slobodskaya O, Pavlakis GN, Chrousos GP: Nuclear recep-
tor coactivator p160 proteins enhance the HIV-1 long termi-
nal repeat promoter by bridging promoter-bound factors
and the Tat-P-TEFb complex.  J Biol Chem 2002, 277:2396-2405.
32. Sgarbanti M, Borsetti A, Moscufo N, Bellocchi MC, Ridolfi B, Nappi F,
Marsili G, Marziali G, Coccia EM, Ensoli B, Battistini A: Modulation
of human immunodeficiency virus 1 replication by interferon
regulatory factors.  J Exp Med 2002, 195:1359-1370.
33. Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E: Transcrip-
tion factor binding sites downstream of the human immuno-
deficiency virus type 1 transcription start site are important
for virus infectivity.  J Virol 1997, 71:6113-6127.
34. Thornton AM, Ogryzko VV, Dent A, Sharf R, Levi BZ, Kanno Y,
Staudt LM, Howard BH, Ozato K: A dominant negative mutant
of an IFN regulatory factor family protein inhibits both type
I and type II IFN-stimulated gene expression and antiprolif-
erative activity of IFNs.  J Immunol 1996, 157:5145-5154.
35. Herrmann CH, Carroll RG, Wei P, Jones KA, Rice AP: Tat-associ-
ated kinase, TAK, activity is regulated by distinct mecha-
nisms in peripheral blood lymphocytes and promonocytic
cell lines.  J Virol 1998, 72:9881-9888.
36. Van 't Wout AB, Swain JV, Schindler M, Rao U, Pathmajeyan MS, Mul-
lins JI, Kirchhoff F: Nef induces multiple genes involved in cho-
lesterol synthesis and uptake in human immunodeficiency
virus type 1-infected T cells.  J Virol 2005, 79:10053-10058.
37. Krishnan V, Zeichner SL: Alterations in the expression of
DEAD-box and other RNA binding proteins during HIV-1
replication.  Retrovirology 2004, 1:42.
38. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: His-
tone deacetylases and cancer: causes and therapies.  Nat Rev
Cancer 2001, 1:194-202.
39. Brigati C, Giacca M, Noonan DM, Albini A: HIV Tat, its TARgets
and the control of viral gene expression.  FEMS Microbiol Lett
2003, 220:57-65.
40. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky
ML, Nakatani Y, Evans RM: Nuclear receptor coactivator ACTR
is a novel histone acetyltransferase and forms a multimeric
activation complex with P/CAF and CBP/p300.  Cell 1997,
90:569-580.
41. El Kharroubi A, Martin MA: cis-acting sequences located down-
stream of the human immunodeficiency virus type 1 pro-
moter affect its chromatin structure and transcriptional
activity.  Mol Cell Biol 1996, 16:2958-2966.
42. Battistini A, Marsili G, Sgarbanti M, Ensoli B, Hiscott J: IRF regula-
tion of HIV-1 long terminal repeat activity.  J Interferon Cytokine
Res 2002, 22:27-37.
43. Marsili G, Borsetti A, Sgarbanti M, Remoli AL, Ridolfi B, Stellacci E,
Ensoli B, Battistini A: On the role of interferon regulatory fac-
tors in HIV-1 replication.  Ann N Y Acad Sci 2003, 1010:29-42.
44. Sgarbanti M, Marsili G, Remoli AL, Ridolfi B, Stellacci E, Borsetti A,
Ensoli B, Battistini A: Analysis of the signal transduction path-
way leading to human immunodeficiency virus-1-induced
interferon regulatory factor-1 upregulation.  Ann N Y Acad Sci
2004, 1030:187-195.
45. Emiliani S, Van Lint C, Fischle W, Paras PJ, Ott M, Brady J, Verdin E:
A point mutation in the HIV-1 Tat responsive element is
associated with postintegration latency.  Proc Natl Acad Sci U S
A 1996, 93:6377-6381.
46. Emiliani S, Fischle W, Ott M, Van Lint C, Amella CA, Verdin E: Muta-
tions in the tat gene are responsible for human immunodefi-
ciency virus type 1 postintegration latency in the U1 cell line.
J Virol 1998, 72:1666-1670.
47. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, Bar-
stad P, Kovacs J, Fauci AS, Folks TM: Monokine regulation of
human immunodeficiency virus-1 expression in a chronically
infected human T cell clone.  J Immunol 1989, 142:431-438.
48. Perez VL, Rowe T, Justement JS, Butera ST, June CH, Folks TM: An
HIV-1-infected T cell clone defective in IL-2 production and
Ca2+ mobilization after CD3 stimulation.  J Immunol 1991,
147:3145-3148.
49. Folks TM, Justement J, Kinter A, Schnittman S, Orenstein J, Poli G,
Fauci AS: Characterization of a promonocyte clone chroni-
cally infected with HIV and inducible by 13-phorbol-12-myr-
istate acetate.  J Immunol 1988, 140:1117-1122.
50. Butera ST, Perez VL, Wu BY, Nabel GJ, Folks TM: Oscillation of the
human immunodeficiency virus surface receptor is regu-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2005, 2:73 http://www.retrovirology.com/content/2/1/73
Page 14 of 14
(page number not for citation purposes)
lated by the state of viral activation in a CD4+ cell model of
chronic infection.  J Virol 1991, 65:4645-4653.
51. Hazan U, Thomas D, Alcami J, Bachelerie F, Israël N, Yssel H, Vireli-
zier JL, Arenzana-Seisdedos F: Stimulation of human T-cell clone
with anti-CD3 or tumor necrosis factor induces NF-kappa B
translocation but not human immunodeficiency virus 1
enhancer-dependent transcription.  Proc Natl Acad Sci USA 1990,
87:7861-7865.
52. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY,
Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid
receptor coactivator amplified in breast and ovarian cancer.
Science 1997, 277:965-968.
53. El Kharroubi A, Verdin E: Protein-DNA interactions within
DNase I-hypersensitive sites located downstream of the
HIV-1 promoter.  J Biol Chem 1994, 269:19916-19924.
54. Brussel A, Sonigo P: Evidence for gene expression by uninte-
grated human immunodeficiency virus type 1 DNA species.
J Virol 2004, 78:11263-11271.
55. Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, Baleux F, Bri-
and P, Hazan U: Spontaneous mutations in the env gene of the
human immunodeficiency virus type 1 NDK isolate are asso-
ciated with a CD4-independent entry phenotype.  J Virol 1998,
72:512-519.